Latest Stocks: Chardan Capital Trims Alnylam Pharmaceuticals, Inc. (ALNY) Target Price to $95.00

Latest Stocks: Chardan Capital Trims Alnylam Pharmaceuticals, Inc. (ALNY) Target Price to $95.00

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its price target cut by Chardan Capital from $110.00 to $95.00 in a research report issued on Monday, May 15th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s price objective indicates a potential upside of 35.85% from the company’s previous close.

A number of other research analysts have also issued reports on the stock. Credit Suisse Group AG restated a “hold” rating and issued a $50.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the company an “equal weight” rating in a report on Monday, May 8th. BMO Capital Markets initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, April 17th. They set an “outperform” rating and a $73.00 price objective for the company. FBR & Co reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, March 20th. Finally, Vetr raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $72.50 price objective for the company in a research note on Thursday, March 16th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $70.50.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 69.93 on Monday. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $80.11. The company’s market capitalization is $6.03 billion. The firm has a 50-day moving average of $60.18 and a 200-day moving average of $49.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. Alnylam Pharmaceuticals’s quarterly revenue was up 160.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.21) earnings per share. Analysts forecast that Alnylam Pharmaceuticals will post ($5.31) earnings per share for the current year. In related news, EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at $1,597,275. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,125 shares of company stock valued at $4,325,000. Company insiders own 4.00% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock worth $661,530,000 after buying an additional 35,803 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares during the period. Dodge & Cox acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $344,633,000. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock worth $290,086,000 after buying an additional 200,890 shares during the period. Finally, BlackRock Inc. raised its position in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares during the period. Institutional investors own 88.70% of the company’s stock. Alnylam Pharmaceuticals Company Profile

Related posts

Leave a Comment